Results 1 to 10 of about 6,727 (169)

Anticancer sensitivities and biological characteristics of HCT116 cells resistant to the selective poly(ADP‐ribose) glycohydrolase inhibitor [PDF]

FEBS Open Bio
Poly(ADP‐ribose) glycohydrolase (PARG) is a key enzyme involved in poly(ADP‐ribose) (PAR) degradation and is considered a potential anticancer target. We previously investigated resistance mechanisms to the PARG inhibitor PDD00017273 in human colorectal ...
Kaede Tsuda, Yoko Ogino, Akira Sato
doaj   +3 more sources

Prospects for PARG inhibitors in cancer therapy [PDF]

Journal of Molecular Cell Biology
Abstract Poly(ADP-ribose) glycosylhydrolase (PARG) is an enzyme involved in hydrolyzing the ribose–ribose bonds present in poly(ADP-ribose) (PAR), which are primarily found in the nucleus. Along with poly(ADP-ribose) polymerase, PARG regulates the level of PAR in cells, playing a crucial role in DNA maintenance and repair processes ...
Ji Jing, Zu Ye, Ye Zu
exaly   +4 more sources

Elevated TRIM25 Impairs Poly (ADP-ribose) Metabolism via PARG Degradation and Mediates Compression-Induced Intervertebral Disc Degeneration. [PDF]

Adv Sci (Weinh)
TRIM25 acts as a multifunctional hub driving intervertebral disc degeneration under mechanical stress. Mechanical compression significantly upregulates TRIM25 expression, establishing it as a key E3 ubiquitin ligase platform. TRIM25 targets PARG and Ku80 via distinct molecular interfaces, triggering their ubiquitination and degradation.
Cheng Z, Gao H, Wu W, Shi P, Chen X, Yu Z, Wu W, Zhao K, Yang C, Zhang Y.   +9 more
europepmc   +2 more sources

Loss‐of‐function genetic screen unveils synergistic efficacy of PARG inhibition with combined 5‐fluorouracil and irinotecan treatment in colorectal cancer [PDF]

Clinical and Translational Medicine
Background Colorectal cancer (CRC) remains a major global health concern, partly due to resistance to therapy and the lack of new effective treatments for advanced disease.
Cristina Queralt, Cristina Moreta‐Moraleda, Marta Costa, Ferran Grau‐Leal, Jeannine Diesch, Carla Vendrell‐Ayats, Eva Musulén, Roni H G Wright, Cristina Bugés, José Luis Manzano, Sara Cabrero‐de las Heras, Johannes Zuber, Marcus Buschbeck, Sonia‐V Forcales, Eva Martínez‐Balibrea   +14 more
doaj   +2 more sources

Regulation of Wnt Singaling Pathway by Poly (ADP-Ribose) Glycohydrolase (PARG) Silencing Suppresses Lung Cancer in Mice Induced by Benzo(a)pyrene Inhalation Exposure

Frontiers in Pharmacology, 2019
Benzo(a)pyrene (BaP) is a polycyclic aromatic hydrocarbon that specifically causes cancer and is widely distributed in the environment. Poly (ADP-ribosylation), as a key post-translational modification in BaP-induced carcinogenesis, is mainly catalyzed ...
Zhuoying Zeng, Yingbin Fu, Linqing Yang   +2 more
exaly   +3 more sources

PARG Mutation Uncovers Critical Structural Determinant for Poly(ADP-Ribose) Hydrolysis and Chromatin Regulation in Embryonic Stem Cells [PDF]

Cells
Poly(ADP-ribosyl)ation is a crucial posttranslational modification that governs gene expression, chromatin remodeling, and cellular homeostasis. This dynamic process is mediated by the opposing activities of poly(ADP-ribose) polymerases (PARPs), which ...
Yaroslava Karpova, Sara Piatz, Guillaume Bordet, Alexei V. Tulin   +3 more
doaj   +2 more sources

PARG inhibition suppresses breast cancer progression and potentiates immunoresponse through MTDH degradation mediated by E3 ligase ITCH-dependent ubiquitination [PDF]

npj Breast Cancer
PARG plays an important role in cancer progression and immunoresponse, but its role in breast cancer is not yet fully elucidated. The advanced breast cancer is still a persistent challenge in clinical oncology.
Junnai Wang, Yanhua Dong, Weiwei Lun, Manman Nai, Yajing Shi, Jianfang Geng, Wenhui Cai, Jiaxi Liu, Hongyu Li, Lei Li   +9 more
doaj   +2 more sources

PARG inhibition in ATM-deficient prostate cancer: from mechanistic discovery to therapeutic potential [PDF]

Journal of Translational Medicine
Background ATM deficiency is frequently observed in castration-resistant prostate cancer (CRPC). However, effective therapeutic vulnerabilities associated with this genetic alteration remain poorly defined.
Xuan Zhou, Chunyu Guo, Zhiguo Fan, Yihaoyun Lou, Zhiying Yue, Weidong Xu, Zhixiang Xin, Shancheng Ren   +7 more
doaj   +2 more sources

PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair

EMBO Journal
Targeting poly(ADP-ribose) glycohydrolase (PARG) is currently explored as a therapeutic approach to treat various cancer types, but we have a poor understanding of the specific genetic vulnerabilities that would make cancer cells susceptible to such a ...
Hendrik Johannes Kuiken, Jos Jonkers, Roderick Beijersbergen   +2 more
exaly   +2 more sources

Purification of Recombinant Human PARG and Activity Assays [PDF]

Methods in Molecular Biology, 2017
The purification of Poly(ADP-ribose) glycohydrolase (PARG) from overexpressing bacteria Escherichia coli is described here to a fast and reproducible one chromatographic step protocol. After cell lysis, GST-PARG-fusion proteins from the crude extract are affinity purified by a Glutathione 4B Sepharose chromatographic step.
Elea Heberle, Valerie Schreiber, Françoise Dantzer   +2 more
exaly   +3 more sources